SCHEDULE: FMR LLC & Abigail Johnson Boost Immunovant Stake to 8.4%
Beneficial Ownership Disclosure
FMR LLC and its affiliates, along with Abigail P. Johnson, have reported a beneficial ownership of 8.4% of Immunovant Inc.'s common stock as of September 30, 2025.
Summary
- FMR LLC and Abigail P. Johnson collectively beneficially own 14,729,554.78 shares of Immunovant Inc. common stock.
- This represents an 8.4% stake in the company's common stock.
- FMR LLC, a Delaware-organized parent holding company, holds these shares through various subsidiaries, including Fidelity Management & Research Company LLC, Fidelity Management Trust Company, and Strategic Advisers LLC.
- Abigail P. Johnson, as Director, Chairman, and Chief Executive Officer of FMR LLC, is deemed to beneficially own the same aggregate amount of shares due to her control over FMR LLC.
- The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Immunovant Inc.
Sentiment
Score: 7
Explanation: The filing indicates a substantial beneficial ownership stake by a major institutional investor, FMR LLC, and its principal, Abigail P. Johnson, in Immunovant Inc. This suggests a degree of confidence from a respected financial entity, which is generally a positive signal for the company's stability and long-term prospects. However, as a passive 13G filing, it does not provide new operational or financial performance data.
Positives
- A significant institutional investor, FMR LLC (Fidelity), holds an 8.4% stake, indicating a degree of confidence in Immunovant Inc.
- The investment is held in the ordinary course of business, suggesting a long-term investment perspective rather than an activist stance.
- This filing is an Amendment No. 3, implying a continued or adjusted significant ownership by FMR LLC and Abigail P. Johnson.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding Immunovant Inc.'s future performance or strategic direction.
Management Comments
- FMR LLC and Abigail P. Johnson certified that their beneficial ownership of Immunovant Inc. common stock was acquired and is held in the ordinary course of business, not for the purpose of changing or influencing the control of the issuer.
- FMR LLC and its direct and indirect subsidiaries, along with Abigail P. Johnson, certified that the information set forth in this statement is true, complete, and correct to the best of their knowledge and belief.
Industry Context
The disclosure of a significant stake by a major institutional investor like FMR LLC (Fidelity) in a biotechnology company such as Immunovant Inc. can signal market confidence in the company's pipeline, technology, or long-term growth prospects. Such investments are common in the biotech sector, where long-term capital is often required for research and development.
Comparison to Industry Standards
- FMR LLC, through its various investment advisory and trust entities, is a prominent institutional investor with a diversified portfolio across numerous industries, including biotechnology. Their 8.4% stake in Immunovant Inc. is a substantial position, comparable to other significant institutional holdings in emerging biotech firms where long-term growth potential is a key investment driver.
- While specific comparable companies or projects are not mentioned, FMR LLC's investment strategy typically involves identifying companies with strong fundamentals and growth potential, aligning with common industry standards for institutional investment in the life sciences sector.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake by FMR LLC may instill greater confidence among existing and potential shareholders, potentially contributing to stock stability or positive sentiment.
- Company Management: A large, passive institutional investor like FMR LLC typically provides a stable shareholder base, allowing management to focus on long-term strategic objectives without immediate activist pressure.
Key Dates
| Date | Description |
|---|---|
| 2023-01-03 | Effective date of Power of Attorney for FMR LLC and its direct and indirect subsidiaries. |
| 2023-01-10 | Date of Schedule 13G filing by FMR LLC where the Power of Attorney (accession number: -23-000003) was incorporated by reference. |
| 2023-01-26 | Effective date of Power of Attorney for Abigail P. Johnson. |
| 2023-01-31 | Date of Schedule 13G filing by FMR LLC where Abigail P. Johnson's Power of Attorney (accession number: -23-000038) was incorporated by reference. |
| 2025-09-30 | Date of event requiring this statement, representing the beneficial ownership calculation date. |
| 2025-11-04 | Signature date for FMR LLC and Abigail P. Johnson on this Schedule 13G Amendment No. 3 filing. |
Recommendation
holdThe filing indicates a substantial, passive ownership stake by FMR LLC and Abigail P. Johnson, representing 8.4% of Immunovant Inc. This signals institutional confidence in the company. However, as a Schedule 13G, it provides no new operational or financial data to warrant a change in investment thesis. The investment is stated to be in the ordinary course of business, not for control, suggesting a long-term, non-activist position. Investors should hold their positions and await further operational updates or financial results from Immunovant Inc. to make more informed decisions.
Keywords
Immunovant Inc, IMVT, FMR LLC, Fidelity, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Institutional Investment, Common Stock, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.